Jazz Pharmaceuticals (JAZZ) Current Deferred Revenue (2010 - 2023)

Jazz Pharmaceuticals' Current Deferred Revenue history runs 14 years deep, the most recent figure standing at $4000.0 for Q3 2023.

• In Q3 2023, Current Deferred Revenue fell 99.54% year-over-year to $4000.0; the TTM figure through Sep 2023 stood at $4000.0 (down 99.54% YoY), while the FY2022 annual figure was $463000.0, down 81.89% from the prior year.
• Current Deferred Revenue for Q3 2023 stood at $4000.0, roughly flat from $4000.0 in the prior quarter.
• The five-year high for Current Deferred Revenue was $11.9 million in Q2 2019, with the low at $4000.0 in Q1 2023.
• The 5-year median for Current Deferred Revenue is $3.3 million (2021), against an average of $4.0 million.
• The sharpest annual moves came in 2019 and 2023: Current Deferred Revenue soared 84.96% in 2019, then slumped 99.76% in 2023.
• Jazz Pharmaceuticals' Current Deferred Revenue stood at $9.6 million in 2019, then tumbled by 49.26% to $4.9 million in 2020, then plunged by 47.42% to $2.6 million in 2021, then tumbled by 81.89% to $463000.0 in 2022, then slumped by 99.14% to $4000.0 in 2023.
• Business Quant data shows JAZZ's Current Deferred Revenue at $4000.0 in Q3 2023, $4000.0 in Q2 2023, and $4000.0 in Q1 2023.